VENUSREM — Venus Remedies Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- IN₹5.17bn
- IN₹4.85bn
- IN₹5.56bn
- 46
- 44
- 96
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.5 | ||
| PEG Ratio (f) | 0.71 | ||
| EPS Growth (f) | 23.49% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | 77.01 | ||
| Price to Sales | 0.97 | ||
| EV to EBITDA | 7.96 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.92% | ||
| Return on Equity | 5.53% | ||
| Operating Margin | 5.87% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 3,218.93 | 3,393.34 | 5,481.23 | 5,986.5 | 5,555.1 | 6,111 | 7,088 | 8.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -18.14 | -35.6 | +24.79 | +22.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.
Directors
- Pawan Chaudhary CHM (51)
- Neha Kodan CCO
- Manu Chaudhary MDR (45)
- Peeyush Jain DMD
- Ashutosh Jain EDR
- Suresh Chadha NID
- Pravindra Chauhan NID
- Savita Gupta NID (50)
- Navdeep Sud NID (61)
- Gilbert Wenzel NID (57)
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- September 15th, 1989
- Public Since
- February 15th, 1995
- No. of Shareholders
- 22,258
- No. of Employees
- 998
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 13,366,988
- Address
- 51-52, Industrial Area, Phase-1, PANCHKULA, 134113
- Web
- https://www.venusremedies.com/
- Phone
- +91 1722933090
- Auditors
- Vinod Kumar & Associates
Upcoming Events for VENUSREM
Q4 2023 Venus Remedies Ltd Earnings Release
Similar to VENUSREM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Ajanta Pharma
National Stock Exchange of India
FAQ
What is the Venus Remedies share price?
As of Today at 18:22 UTC, shares in Venus Remedies are trading at IN₹386.55. This share price information is delayed by 15 minutes.
How has the Venus Remedies share price performed this year?
Shares in Venus Remedies last closed at IN₹386.55 and the price had moved by +93.57% over the past 365 days. In terms of relative price strength the Venus Remedies share price has outperformed the S&P BSE 100 Index by +78.79% over the past year.
What are the analyst and broker recommendations for Venus Remedies?
The overall consensus recommendation for Venus Remedies is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Venus Remedies dividend yield?
Venus Remedies does not currently pay a dividend.
Does Venus Remedies pay a dividend?
Venus Remedies does not currently pay a dividend.
When does Venus Remedies next pay dividends?
Venus Remedies does not currently pay a dividend.
How do I buy Venus Remedies shares?
To buy shares in Venus Remedies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Venus Remedies?
As of the previous close price of IN₹386.55, shares in Venus Remedies had a market capitalisation of IN₹5.17bn.
Where are Venus Remedies shares listed?
Here are the trading details for Venus Remedies:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: VENUSREM
What kind of share is Venus Remedies?
Based on an overall assessment of its quality, value and momentum Venus Remedies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Venus Remedies share price forecast for 2023?
The analyst consensus target price for shares in Venus Remedies is IN₹388.00. That is 0.38% above the last closing price of IN₹386.55.
Analysts covering Venus Remedies currently have a consensus Earnings Per Share (EPS) forecast of IN₹24.80 for the next financial year.
What is the trend in the Venus Remedies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Venus Remedies. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +46.81%.
As of the last closing price of IN₹386.55, shares in Venus Remedies were trading +68.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Venus Remedies PE Ratio?
The Venus Remedies PE ratio based on its reported earnings over the past 12 months is 13.5. The shares last closed at IN₹386.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Venus Remedies?
Venus Remedies' management team is headed by:
- Pawan Chaudhary - CHM
- Neha Kodan - CCO
- Manu Chaudhary - MDR
- Peeyush Jain - DMD
- Ashutosh Jain - EDR
- Suresh Chadha - NID
- Pravindra Chauhan - NID
- Savita Gupta - NID
- Navdeep Sud - NID
- Gilbert Wenzel - NID